All aboard as Alteryx adds to analytics cloud and automation

suresh-vittal

As announced at Inspire EMEA 2022, Alteryx has unveiled new enhancements to enable cloud analytics and enterprise readiness.

The enhancements see improvements of Alteryx Machine Learning, which is now powered by the Alteryx Analytics Cloud Platform, designed to allow anyone with a non-data science background to easily build automated machine learning models at scale.

Designer Cloud powered by Trifacta meanwhile has improved the performance of Snowflake data processing. New updates include processing data up to 20x faster when moving data from AWS to Snowflake, enabling users to access and utilize more data sources quickly and easily.

In the 22.3 product release, Alteryx enhances security and speed to enterprise-wide analytics insights, and now supports Azure Active Directory with Alteryx’s Data Connection Manager (DCM).  Users can speed their time to insights with enhanced Google BigQuery connectivity, with 170x performance improvement. The new upgrade allows analysts to work with large data sets where they live, rather than costly processes that impact productivity.

Suresh Vittal, chief product officer at Alteryx, said: “Putting powerful machine learning tools in the hands of everyone and making data science accessible is core to solving the biggest challenges in business today. At Alteryx, we are excited these new product enhancements will help essential in-department knowledge experts to make valuable contributions to the business by delivering outcomes that drive innovation needed to succeed in hypercompetitive landscapes.”

Sajid Sayed, senior director, data science platform at Advarra, said: “Being able to take advantage of Snowflake computing in Alteryx Designer Cloud is a huge advantage for Advarra that allows us to centralize our resource management and investments. These enhancements to Snowflake Pushdown will provide a more streamlined analytics performance and will be a huge advantage for Advarra and our data-driven approach to clinical research.”